Cara Therapeutics reported first quarter 2024 financial results, including net sales of KORSUVA injection of approximately $1.8 million and collaborative revenue of approximately $800,000. The company's net loss was $30.7 million, or $(0.56) per basic and diluted share. Cash, cash equivalents and marketable securities totaled $69.8 million at the end of the quarter.

Cara Therapeutics reported a net loss of $32.3 million for Q4 2023. The company is prioritizing its clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP). Enrollment in KOURAGE 1 Part A was completed ahead of schedule, with topline efficacy and safety results expected in Q3 2024. The company's cash runway extends into 2026.

Cara Therapeutics reported Q3 2023 total revenue of $4.9 million, including collaborative revenue of $1.9 million from KORSUVA injection. The company's net loss was $28.0 million, or $(0.52) per share. A non-dilutive financing agreement with HealthCare Royalty for up to $40 million is expected to extend the cash runway into 2025.

Cara Therapeutics reported Q2 2023 total revenue of $6.9 million, which includes collaborative revenue of $5.4 million from KORSUVA injection sales. Net loss for the quarter was $31.5 million, or $(0.58) per basic and diluted share. The company's cash, cash equivalents, and marketable securities totaled $101.7 million as of June 30, 2023.

Cara Therapeutics reported Q1 2023 financial results, featuring $6.2 million in total revenue, including $2.8 million from KORSUVA injection sales. The company's net loss was $26.7 million, or $(0.49) per share. Vial orders for KORSUVA injection more than doubled quarter-over-quarter, indicating increased demand. The company expects its cash to fund operations into the second half of 2024.

Cara Therapeutics reported Q4 2022 total revenue of $3.3 million, including collaborative revenue of $1.1 million from KORSUVA injection. Net loss for the quarter was $30.3 million, or $(0.56) per share. The company's cash, cash equivalents, and marketable securities totaled $156.7 million as of December 31, 2022.

Cara Therapeutics reported a net revenue of $16.2 million for Q3 2022, which included $7.4 million in profit-sharing revenue from KORSUVA injection. The company's net loss was $23.2 million, or $(0.43) per basic and diluted share. The company is focused on maximizing the potential of its nephrology and dermatology franchises.

Cara Therapeutics reported a net revenue of $23 million for Q2 2022, driven by profit-sharing from KORSUVA™ injection and a milestone payment from the European Commission approval of Kapruvia®. The KOMFORT Phase 2 trial met its primary endpoint in notalgia paresthetica, and the company anticipates a meeting with the FDA in the second half of 2022.

Cara Therapeutics reported a net loss of $27.7 million, or $(0.52) per basic and diluted share, for the first quarter of 2022. Total revenue was $4.8 million, and the company's cash, cash equivalents, and marketable securities totaled $209.6 million.

Cara Therapeutics reported fourth-quarter financial results, with a net loss of $33.4 million, or $(0.63) per basic and diluted share, and total revenue of $0.8 million. The company is preparing for the U.S. commercial launch of KORSUVA injection in April 2022 and advancing its Oral KORSUVA platform in multiple pruritus indications.

Cara Therapeutics reported a net loss of $1.0 million, or $0.02 per basic and diluted share, for the three months ended September 30, 2021. Revenues for the quarter were $20.3 million, primarily from license and milestone fees related to the regulatory approval of KORSUVA injection. The company's cash, cash equivalents, and marketable securities totaled $193.4 million as of September 30, 2021.

Cara Therapeutics reported a net loss of $30.7 million, or $0.61 per share, for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $207.4 million as of June 30, 2021. The FDA granted Priority Review for the NDA filing of KORSUVA Injection in March 2021 with an expected PDUFA target action date of August 23, 2021.

Cara Therapeutics reported a net loss of $23.3 million, or $0.47 per share, for the first quarter of 2021. Total revenue was $1.9 million, primarily consisting of license and milestone fees. Cash, cash equivalents, and marketable securities totaled $228.3 million as of March 31, 2021.

Cara Therapeutics reported a net income of $78.9 million for the fourth quarter of 2020, compared to a net loss of $28.6 million for the same period in 2019. Total revenue was $112.1 million, primarily consisting of license and milestone fees revenue.

Cara Therapeutics reported a net loss of $16.5 million, or $0.35 per share, for the third quarter of 2020, compared to a net loss of $32.8 million, or $0.74 per share, for the same period of 2019. Total revenue was $9.3 million for the three months ended September 30, 2020, compared to $5.8 million during the same period of 2019.

Cara Therapeutics reported a net loss of $25.1 million and total revenue of $5.6 million for the three months ended June 30, 2020. The company is on track to submit its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter.

Cara Therapeutics reported a net loss of $28.9 million and total revenue of $8.1 million for the first quarter of 2020. The company is on track to submit an NDA to the FDA for KORSUVA Injection in the second half of 2020.

Cara Therapeutics reported a net loss of $28.6 million for the fourth quarter of 2019, compared to a net loss of $20.7 million for the same period in 2018. The company's cash, cash equivalents, and marketable securities totaled $218.2 million at the end of 2019.